Major Gastrointestinal Disorders and Peritoneal Infections DRG Reimbursement

DRG 371 encompasses major gastrointestinal disorders and peritoneal infections when a Major Complication or Comorbidity is present, reflecting high-acuity abdominal conditions that drive inpatient resource use. This matters for inpatient reimbursement because Medicare payment is adjusted upward for the increased intensity, length of stay, and cost associated with these complex cases.

DRG 371 Overview

DRG 371 covers major gastrointestinal disorders and peritoneal infections with a Major Complication or Comorbidity, including severe intra-abdominal infections, complicated bowel obstructions, and other high-acuity abdominal surgical or medical conditions. This Diagnosis-Related Group groups patients with significant physiologic derangement that typically require intensive inpatient care, prolonged hospitalization, and complex resource use. It matters for Medicare payment because cases assigned here generate higher inpatient reimbursement to reflect the greater intensity of services and costs. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and therefore influence Medicare inpatient payment.

Acute surgical and critical care intervention trials: randomized or observational studies evaluating timing and technique of source control (such as emergency laparotomy, percutaneous drainage, or minimally invasive approaches) and optimized perioperative resuscitation strategies for patients presenting with severe gastrointestinal perforations, ischemic bowel, necrotizing enterocolitis in adults, or advanced peritonitis with hemodynamic instability. These studies focus on the immediate inpatient phase, enrolling patients with life-threatening major GI disorders and peritoneal infections often requiring ICU-level care, and measure short-term mortality, organ failure, and complications. Results inform surgeons, intensivists, and payers about interventions that can reduce length of stay, ICU utilization, and high-cost complications that drive DRG resource use.
Comparative effectiveness and antimicrobial stewardship studies: trials comparing antimicrobial regimens, duration of therapy, and diagnostic-guided de-escalation strategies for complex intra-abdominal infections and secondary peritonitis in patients with comorbid conditions (eg, immunosuppression, chronic liver disease, or diabetes) or multidrug-resistant organisms. These studies enroll heterogeneous inpatient populations grouped under this DRG to determine equivalence or superiority in clinical cure, readmission, and emergence of resistance while capturing adverse events. Findings are directly relevant to hospital antibiograms, pharmacy budgeting, and payer concerns about antimicrobial costs and readmission penalties.
Post-discharge outcomes, rehabilitation, and readmission reduction research: longitudinal cohort studies and interventional trials that test care-transition models, early outpatient follow-up, nutrition and wound-care protocols, and telemedicine monitoring to prevent readmissions and late complications (such as recurrent abscess, fistula, or malnutrition) among survivors of major GI surgery or treated peritoneal infections. These studies target discharged patients at high risk for rehospitalization due to complex needs, prolonged antibiotic courses, or ongoing drains, and measure 30- to 90-day readmissions, functional recovery, and total episode-of-care costs. Evidence supports providers and payers in designing post-acute services and bundled payment strategies to lower downstream costs associated with this DRG.

Acute surgical and critical care intervention trials: randomized or observational studies evaluating timing and technique of source control (such as emergency laparotomy, percutaneous drainage, or minimally invasive approaches) and optimized perioperative resuscitation strategies for patients presenting with severe gastrointestinal perforations, ischemic bowel, necrotizing enterocolitis in adults, or advanced peritonitis with hemodynamic instability. These studies focus on the immediate inpatient phase, enrolling patients with life-threatening major GI disorders and peritoneal infections often requiring ICU-level care, and measure short-term mortality, organ failure, and complications. Results inform surgeons, intensivists, and payers about interventions that can reduce length of stay, ICU utilization, and high-cost complications that drive DRG resource use.
Comparative effectiveness and antimicrobial stewardship studies: trials comparing antimicrobial regimens, duration of therapy, and diagnostic-guided de-escalation strategies for complex intra-abdominal infections and secondary peritonitis in patients with comorbid conditions (eg, immunosuppression, chronic liver disease, or diabetes) or multidrug-resistant organisms. These studies enroll heterogeneous inpatient populations grouped under this DRG to determine equivalence or superiority in clinical cure, readmission, and emergence of resistance while capturing adverse events. Findings are directly relevant to hospital antibiograms, pharmacy budgeting, and payer concerns about antimicrobial costs and readmission penalties.
Post-discharge outcomes, rehabilitation, and readmission reduction research: longitudinal cohort studies and interventional trials that test care-transition models, early outpatient follow-up, nutrition and wound-care protocols, and telemedicine monitoring to prevent readmissions and late complications (such as recurrent abscess, fistula, or malnutrition) among survivors of major GI surgery or treated peritoneal infections. These studies target discharged patients at high risk for rehospitalization due to complex needs, prolonged antibiotic courses, or ongoing drains, and measure 30- to 90-day readmissions, functional recovery, and total episode-of-care costs. Evidence supports providers and payers in designing post-acute services and bundled payment strategies to lower downstream costs associated with this DRG.

OpenPayer

Summary & Overview

Major Gastrointestinal Disorders and Peritoneal Infections with MCC: Inpatient Reimbursement Overview

DRG 371 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes